0001) in the adjusted model No significant dose-relationship bet

0001) in the adjusted model. No significant dose-relationship between BB and mortality could be demonstrated (p=0.4). The median life-time after cohort entry was 4.0 years for users of BB compared with 1.7 years for non-users (p<0.0001). Among the patients with severe decompensated cirrhosis, we also

found lower mortality rates among the user of BB, but the difference did not reach statistical significance (HR=0.73, p=0.1). This was also the case for the subgroup of patients with diuretic resistant ascites (HR=0.87, p=0.6). The use of diuretics was related with a markedly decreased mortality learn more in our adjusted analysis (HR=0.18, p<0.0001) and we found that the use of BB and diuretics interacted significantly when used as predictors of death (p=0.002). Nevertheless, the combination of BB and diuretics was not superior compared to treatment with only BB or diuretics with regard to survival (p=0.8). This is the first

nationwide population study of the effect of BB on mortality among patients with cirrhosis and ascites, and we LY2109761 found to use of BB to be related with reduced risk of death. Disclosures: The following people have nothing to disclose: Ulrich C. Bang, Thomas Benfield, Lars Hyldstrup, Jens-Erik B. Jensen, Flemming Bendtsen Background: The Drug Induced Liver Injury Network (DILIN) prospectively assesses patients with drug induced liver injury (DILI), as well as herbal and dietary supplement (HDS) induced liver injury (HILI). Aim: To describe, compare and contrast the clinical features and outcomes in patients with HILI and DILI enrolled in the prospective study. Methods: Between 2003 and March 2013, DILIN enrolled 1035 patients; 845 were adjudicated as probably, very likely or definitely due to the suspected agent. 136 (16%) cases were attributed to an HDS. Isotretinoin Results: Forty-four (35%) HILI cases were attributed to bodybuilding products, the most common HDS class implicated. Eighty-five

(62%) cases were attributed to other products, and 7 patients took combinations of agents. The proportion of cases attributed to HDS products increased from 7% in 2004-2005 to 20% in 2012 and the increase occurred with body building (2% to 7%) as well as other HDS products (5% to 12%) (Table). Among HILI cases due to bodybuilding products, all were men (mean age 33) with jaundice and pruritus, and none resulted in death or transplantation. In contrast, HILI cases due to other HDS products more closely resembled DILI in several ways; 35% were men (vs 37% in DILI); average age 48 (vs 50) years; 78% (vs 68%) had jaundice; and 68% (vs 58%) were hospitalized. Serum total bilirubin values at onset were higher (median mg/dL) for bodybuilding HILI than for other HDS (7.9) or drug cases (4.3, P <. 001). Serum ALT values were lower (median 194 IU/L vs. 1100 for other HDS and 634 for drugs, P<. 001).

Comments are closed.